Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer. (4th November 2015) - Beer, Tomasz M; Vogelzang, Nicholas; Bartůňková, Jiřina; Miller, Kurt; Oh, William; Oudard, Stephane; Pandha, Hardev; Sartor, A Oliver; Špíšek, Radek; Toole, Timothy O; Borgstein, Niels G; Gerritsen, Winald R